Abbott Laboratories vs. TG Therapeutics, Inc.
Abbott Laboratories (ABT) comes out ahead, leading on 6 of 9 compared factors.
Size & Scale
| ABT | TGTX | |
|---|---|---|
| Market Cap | $191.92 billion | $7.58 billion |
| Revenue (TTM) | $46.59 billion | $799.54 million |
| Net Income (TTM) | $5.42 billion | $441.49 million |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | TGTX | |
|---|---|---|
| P/E Ratio | 36.00 | 17.72 |
| Price / Book | 3.71 | 12.54 |
| Price / Sales | 4.12 | 9.48 |
ABT leads on 2 of 3 valuation factors.
Profitability
| ABT | TGTX | |
|---|---|---|
| Net Margin | 11.65% | 55.22% |
| Return on Equity | 10.48% | 73.08% |
TGTX leads on 2 of 2 profitability factors.
Dividend
| ABT | TGTX | |
|---|---|---|
| Dividend Yield | 2.27% | — |
| Payout Ratio | 81.55 | — |
ABT and TGTX split the dividend factors evenly.
Risk & Sentiment
| ABT | TGTX | |
|---|---|---|
| Short Interest | 0.57% | 11.01% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, TGTX overview, TGTX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.